Psoriasis

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Psoriasis.php on line 2
Psoriasis

LE WE PMID CA

Psoriasis

3016

Psoriasis

Adalimumab ttTNFalpha

Aids

Alefacept

Arthritis (rheumatoid)

Asthma (BASKET)

Atopic dermatitis

c Jun

Cardiovascular risk

Efalizumab ttLFA1

Hand and wrist (MRT)

Infliximab ttTNFalpha

Interleukin22 IL TIF

Interleukin23

Interleukin24 MDA7

Joint (MRT)

Keratinocyte

NK cells

Psoriasis

Receptor (Catecholamines beta)

STAT6

T cell (Th17)

T cell (Th2)

Tocilizumab ttIL6

Ustekinumab ttIL12 ttIL23

2006 1	Psoriasis and its management. [16916825] BMJ 333(7564): 380-4 (2006)
1986 2	Psoriasis. [3089359] Br Med J (Clin Res Ed) 292(6537): 1693-6 (1986)
1974 3	Diseases of the skin. Psoriasis. [4592992] Br Med J 1(5896): 27-9 (1974)
2005 4	Topical therapies for psoriasis: evidence-based review. [15856971] Can Fam Physician 51(): 519-25 (2005)
2009 5	Psoriasis--new insights into pathogenesis and treatment. [19564982] Dtsch Arztebl Int 106(1-2): 11-8, quiz 19 (2009)
2009 6	Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. [19707417] Biologics 3(-): 303-18 (2009)
2007 7	Efalizumab in the treatment of psoriasis. [19707339] Biologics 1(3): 301-9 (2007)
2010 8	Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. [20635831] J Manag Care Pharm 16(6): 402-16 (2010)
2004 9	Advancements in the treatment of psoriasis: role of biologic agents. [15298530] J Manag Care Pharm 10(4): 318-25 (2004)
2010 10	Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. [20421912] Ther Clin Risk Manag 6(-): 123-41 (2010)
2006 11	Infliximab (Remicade) in the treatment of psoriatic arthritis. [18360651] Ther Clin Risk Manag 2(4): 389-400 (2006)
2009 12	Adalimumab for the treatment of psoriasis. [19804689] Health Technol Assess 13 Suppl 2(): 49-54 (2009)
2006 13	Etanercept and efalizumab for the treatment of psoriasis: a systematic review. [17083854] Health Technol Assess 10(46): 1-233, i-iv (2006)
2006 14	Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. [16948890] Health Technol Assess 10(31): iii-iv, xiii-xvi, 1-239 (2006)
2000 15	A systematic review of treatments for severe psoriasis. [11207450] Health Technol Assess 4(40): 1-125 (2000)
2010 16	Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. [20694136] Core Evid 5(-): 11-22 (2010)
2007 17	German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). [17497162] Arch Dermatol Res 299(3): 111-38 (2007)
2004 18	Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis. [14965795] Eur J Dermatol 14(1): 41-5 (2004)
2010 19	Systemic combination treatment for psoriasis: a review. [20574597] Acta Derm Venereol 90(4): 341-9 (2010)
2002 20	Trends and developments in the pharmacological treatment of psoriasis. [12575844] Acta Derm Venereol 82(6): 401-10 (2002)
2008 21	T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. [18408745] J Invest Dermatol 128(5): 1064-7 (2008)
2007 22	Mouse models of psoriasis. [17429444] J Invest Dermatol 127(6): 1292-308 (2007)
2007 23	Follow-up analysis of PSORS9 in 151 Chinese families confirmed the linkage to 4q31-32 and refined the evidence to the families of early-onset psoriasis. [17139270] J Invest Dermatol 127(2): 312-8 (2007)
1999 24	Animal models of psoriasis - what can we learn from them? [10201521] J Invest Dermatol 112(4): 405-10 (1999)
2004 25	Immunopathogenic mechanisms in psoriasis. [14678257] Clin Exp Immunol 135(1): 1-8 (2004)
2002 26	Angiogenesis in psoriasis. [12906316] Angiogenesis 5(4): 231-6 (2002)
2009 27	Treatment recommendations for psoriatic arthritis. [18952643] Ann Rheum Dis 68(9): 1387-94 (2009)
2006 28	Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases? [17038466] Ann Rheum Dis 65 Suppl 3(-): iii22-4 (2006)
2005 29	Psoriatic arthritis imaging: a review of scoring methods. [15708940] Ann Rheum Dis 64 Suppl 2(): ii61-4 (2005)
2005 30	Imaging the joint and enthesis: insights into pathogenesis of psoriatic arthritis. [15708939] Ann Rheum Dis 64 Suppl 2(-): ii58-60 (2005)
2005 31	Psoriatic arthritis and imaging. [15708938] Ann Rheum Dis 64 Suppl 2(): ii55-7 (2005)
2005 32	Psoriatic arthritis assessment tools in clinical trials. [15708937] Ann Rheum Dis 64 Suppl 2(-): ii49-54 (2005)
2005 33	Psoriasis pathophysiology: current concepts of pathogenesis. [15708932] Ann Rheum Dis 64 Suppl 2(-): ii30-6 (2005)
2005 34	Classification and diagnostic criteria for psoriatic arthritis. [15708931] Ann Rheum Dis 64 Suppl 2(): ii3-8 (2005)
2005 35	Immunopathology of psoriasis and psoriatic arthritis. [15708930] Ann Rheum Dis 64 Suppl 2(-): ii26-9 (2005)
2005 36	Psoriasis: epidemiology, clinical features, and quality of life. [15708928] Ann Rheum Dis 64 Suppl 2(-): ii18-23; discussion ii24-5 (2005)
2005 37	Psoriatic arthritis: epidemiology, clinical features, course, and outcome. [15708927] Ann Rheum Dis 64 Suppl 2(-): ii14-7 (2005)
2005 38	Psoriasis treatment: current and emerging directed therapies. [15708946] Ann Rheum Dis 64 Suppl 2(-): ii87-90; discussion ii91-2 (2005)
2005 39	Psoriasis treatment: traditional therapy. [15708945] Ann Rheum Dis 64 Suppl 2(-): ii83-6 (2005)
2005 40	Psoriatic arthritis treatment: biological response modifiers. [15708944] Ann Rheum Dis 64 Suppl 2(): ii78-82 (2005)
2005 41	Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. [15708943] Ann Rheum Dis 64 Suppl 2(-): ii74-7 (2005)
2005 42	Psoriasis assessment tools in clinical trials. [15708941] Ann Rheum Dis 64 Suppl 2(): ii65-8; discussion ii69-73 (2005)
1976 43	Psoriatic arthritis. Follow-up study. [984900] Ann Rheum Dis 35(3): 206-12 (1976)
2009 44	Psoriatic arthritis: from pathogenesis to therapy. [19232079] Arthritis Res Ther 11(1): 214 (2009)
2006 45	Magnetic resonance imaging in psoriatic arthritis: a review of the literature. [16569257] Arthritis Res Ther 8(2): 207 (2006)
2002 46	Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature. [12221673] Am J Hematol 71(1): 41-4 (2002)
2007 47	Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. [17393414] Arthritis Rheum 56(4): 1051-66 (2007)
2004 48	Assessment of patients with psoriatic arthritis: a review of currently available measures. [14730596] Arthritis Rheum 50(1): 24-35 (2004)
2004 49	Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. [15199399] J Clin Invest 113(12): 1664-75 (2004)
2007 50	Psoriatic arthritis as a distinct disease entity. [17244977] J Postgrad Med 53(1): 63-71 (2007)
2009 51	New insights into the pathogenesis and genetics of psoriatic arthritis. [19182814] Nat Clin Pract Rheumatol 5(2): 83-91 (2009)
2003 52	Current concepts and new developments in the treatment of psoriatic arthritis. [12810935] Rheumatology (Oxford) 42(10): 1138-48 (2003)
2004 53	Psoriasis and the new biologic agents: interrupting a T-AP dance. [15210644] CMAJ 170(13): 1933-41 (2004)
2009 54	Progress in understanding the immunopathogenesis of psoriasis. [20096156] Actas Dermosifiliogr 100 Suppl 2(-): 2-13 (2009)
2008 55	Update on the natural history and systemic treatment of psoriasis. [19256309] Adv Dermatol 24(-): 171-96 (2008)
2011 56	Genital psoriasis: A systematic literature review on this hidden skin disease. [20927490] Acta Derm Venereol 91(1): 5-11 (2011)
2010 57	MRI findings in psoriatic arthritis of the hands. [20966327] AJR Am J Roentgenol 195(5): 1187-93 (2010)
2010 58	Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. [19815494] Ann Rheum Dis 69(2): 394-9 (2010)
2007 59	Psoriasis--pathophysiology, conventional, and alternative approaches to treatment. [18069901] Altern Med Rev 12(4): 319-30 (2007)
2002 60	Clinical features of psoriatic arthritis. [11990861] Am J Manag Care 8(6 Suppl): S160-70 (2002)
2002 61	Current perspectives in the recognition and management of psoriatic arthritis: implications for integrated patient care. [11990862] Am J Manag Care 8(6 Suppl): S171-80 (2002)
2006 62	Psoriatic arthritis update. [17121486] Bull NYU Hosp Jt Dis 64(1-2): 25-31 (2006)
2010 63	Psoriatic arthritis - update on pathophysiology, assessment, and management. [20969551] Bull NYU Hosp Jt Dis 68(3): 191-8 (2010)
2011 64	NK cells and psoriasis. [21687543] J Biomed Biotechnol 2011(-): 248317 (2011)
2005 65	Guideline for anti-TNF-alpha therapy in psoriatic arthritis. [15695305] Rheumatology (Oxford) 44(3): 390-7 (2005)
2007 66	Psoriasis: advances in pathophysiology and management. [17989268] Postgrad Med J 83(985): 690-7 (2007)
2005 67	Psoriasis. [15872205] N Engl J Med 352(18): 1899-912 (2005)
2011 68	Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. [21333232] Health Technol Assess 15(10): i-xxi, 1-329 (2011)
2009 69	Ustekinumab for the treatment of moderate to severe psoriasis. [19846031] Health Technol Assess 13 Suppl 3(-): 61-6 (2009)
2009 70	Psoriasis (chronic plaque). [19445765] Clin Evid (Online) 2009(-): - (2009)
2010 71	Childhood psoriasis. [20657115] Indian J Dermatol Venereol Leprol 76(4): 357-65 (2010)
2002 72	Pharmacological interventions for psoriatic arthritis: present and future. [17656934] Indian J Dermatol Venereol Leprol 68(4): 187-97 (2002)
2010 73	Novel drug delivery systems in topical treatment of psoriasis: rigors and vigors. [21079304] Indian J Dermatol Venereol Leprol 76(6): 612-21 (2010)
2010 74	Psoriasis: what is new in nonbiologic systemic therapy in the era of biologics? [21079305] Indian J Dermatol Venereol Leprol 76(6): 622-33 (2010)
2010 75	Newer trends in the management of psoriasis at difficult to treat locations: scalp, palmoplantar disease and nails. [21079306] Indian J Dermatol Venereol Leprol 76(6): 634-44 (2010)
2010 76	Management of psoriatic arthritis. [21079307] Indian J Dermatol Venereol Leprol 76(6): 645-51 (2010)
2011 77	Current effective topical therapies in the management of psoriasis. [21293834] Skin Therapy Lett 16(1): 4-7 (2011)
2010 78	Alefacept treatment for chronic plaque psoriasis. [20361167] Skin Therapy Lett 15(4): 1-3 (2010)
2005 79	New developments in topical sequential therapy for psoriasis. [16292458] Skin Therapy Lett 10(9): 1-4 (2005)
2008 80	Psoriasis as the marker of underlying systemic disease. [18357363] Skin Therapy Lett 13(1): 1-5 (2008)
2008 81	Topical therapy for the management of childhood psoriasis: part I. [18506356] Skin Therapy Lett 13(3): 1-3 (2008)
2008 82	The role of the dermatologist in identification and treatment of the early stages of psoriatic arthritis. [18648715] Skin Therapy Lett 13(4): 4-7 (2008)
2011 83	Usefulness of ultrasound imaging in detecting psoriatic arthritis of fingers and toes in patients with psoriasis. [21461353] Clin Dev Immunol 2011(-): 390726 (2011)
2010 84	Post-genomics and skin inflammation. [20886018] Mediators Inflamm 2010(-): - (2010)
2010 85	Lipid disturbances in psoriasis: an update. [20706605] Mediators Inflamm 2010(-): - (2010)
2008 86	The challenge of early diagnosis of psoriatic arthritis. [18176985] J Rheumatol 35(1): 3-5 (2008)
2012 87	Molecular Mechanisms Governing IL-24 Gene Expression. [22536164] Immune Netw 12(1): 1-7 (2012)
2011 88	Stat6 and c-Jun mediate Th2 cell-specific IL-24 gene expression. [21357535] J Immunol 186(7): 4098-109 (2011)
2008 89	Adalimumab in dermatology. [18754844] Br J Clin Pharmacol 66(5): 618-25 (2008)
2011 90	Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. [21267358] Drug Des Devel Ther 5(-): 41-9 (2011)
2008 91	Review paper: preclinical models of psoriasis. [18587106] Vet Pathol 45(4): 563-75 (2008)
2010 92	Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. [20445552] J Invest Dermatol 130(7): 1785-96 (2010)
2010 93	Molecular dissection of psoriasis: integrating genetics and biology. [19812592] J Invest Dermatol 130(5): 1213-26 (2010)
2010 94	A role for TGFbeta signaling in the pathogenesis of psoriasis. [19710682] J Invest Dermatol 130(2): 371-7 (2010)
2009 95	The IL-23/Th17 axis in the immunopathogenesis of psoriasis. [19322214] J Invest Dermatol 129(6): 1339-50 (2009)
2011 96	Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. [21503693] Curr Rheumatol Rep 13(4): 353-9 (2011)
2008 97	Altered bone remodeling in psoriatic arthritis. [18662512] Curr Rheumatol Rep 10(4): 311-7 (2008)
2007 98	Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. [18177599] Curr Rheumatol Rep 9(6): 461-7 (2007)
2007 99	Unraveling the paradoxes of HIV-associated psoriasis: a review of T-cell subsets and cytokine profiles. [17498423] Dermatol Online J 13(2): 4 (2007)
2011 100	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Ammonium Lactate Lotion 12% and Halobetasol Propionate Ointment 0.05% in the Treatment and Maintenance of Psoriasis. [21386955] J Clin Aesthet Dermatol 4(2): 28-39 (2011)
2011 101	Vitamin D analogs in the treatment of psoriasis: Where are we standing and where will we be going? [22110777] Dermatoendocrinol 3(3): 180-6 (2011)
2007 102	Skin diseases with high public health impact. Psoriasis. [17951158] Eur J Dermatol 17(6): 563-4 (2007)
2007 103	Clinical assessment in psoriatic arthritis. [17828349] Reumatismo 59 Suppl 1(-): 68-72 (2007)
2007 104	Conventional therapy of psoriatic arthritis: evidence-based review. [17828352] Reumatismo 59 Suppl 1(-): 81-4 (2007)
2009 105	Emerging treatments in the management of psoriasis: biological targeting with ustekinumab. [21436972] Clin Cosmet Investig Dermatol 2(-): 95-103 (2009)
2009 106	Biologics in the management of psoriasis. [21436974] Clin Cosmet Investig Dermatol 2(-): 111-28 (2009)
2011 107	Definition of treatment goals for moderate to severe psoriasis: a European consensus. [20857129] Arch Dermatol Res 303(1): 1-10 (2011)
2007 108	The role of dendritic cells in the immunopathogenesis of psoriasis. [17680257] Arch Dermatol Res 299(8): 359-66 (2007)
2006 109	The long-term efficacy and safety of new biological therapies for psoriasis. [16691429] Arch Dermatol Res 298(1): 7-15 (2006)
2007 110	Beta adrenergic receptors in keratinocytes. [17903623] Dermatol Clin 25(4): 643-53, x (2007)
2008 111	Novel immunobiologics for psoriasis. [20040934] Indian J Pharmacol 40(3): 95-102 (2008)
2010 112	New insights in the immunologic basis of psoriasis. [20430301] Semin Cutan Med Surg 29(1): 3-9 (2010)
2007 113	The new psoriasis pathway: toward a unified theory of immunopathogenesis. [20477148] Expert Rev Clin Immunol 3(4): 447-50 (2007)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Psoriasis.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Psoriasis.php on line 92